ArticleCell reports. Medicine2026
A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Anti-MICA/B antibodies that inhibit the shedding hold promise for cancer immunotherapy and are in phase 1 clinical trials. Although MICA/B-shedding inhibition promotes natural killer (NK) cell-driven immunity by NKG2D engagement, the Fc enables antibody-dependent cellular cytotoxicity. We, therefore, engineer the Fc of an anti-MICA/B antibody (clone 7C6) through GAALIE mutations that increase the binding affinity to Fc-activating receptors. 7C6-GAALIE inhibits MICA/B shedding and potently triggers NK cell-effector functions against tumor cells. Furthermore, we establish a model of metastatic prostate cancer with which we formally demonstrate that 7C6-GAALIE is superior to 7C6 as wild-type human IgG1 in inhibiting metastases in Fc gamma receptor-humanized mice. In melanoma and leukemia models, 7C6-GAALIE had a therapeutic efficacy more consistent than that with 7C6 as wild-type human IgG1. Therefore, this study establishes the proof of concept of a next-generation anti-MICA/B antibody for cancer immunotherapy through an Fc optimization that enhances the antibody's ability to elicit NK cell-driven immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.